Heterogeneous vascular dependence of tumor cell populations

American Journal of Pathology

Volumn 158, Issue 4, 2001, Pages 1325-1334

  Yu, Joanne L ^a,b   Rak, Janusz W ^c   Carmeliet, Peter ^d   Nagy, Andras ^e   Kerbel, Robert S ^a,b   Coomber, Brenda L ^f  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HOE 33342; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL HETEROGENEITY; CELL HYPOXIA; CELL INVASION; CELL LABELING; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; GENOTYPE; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION; XENOGRAFT;

EID: 0035069527     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64083-7     Document Type: Article

References (37)

1. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
2. Acquired drug resistance driven by tumor cell genetic instability: Circumvention by direct acting anti-angiogenic vascular targeting agents
3. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
4. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy
5. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alpha-2a
6. Treating cancer by inhibiting angiogenesis: New hopes and potential pitfalls
7. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
8. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
9. Intraneoplastic diversity
10. Biological diversity in metastatic neoplasms: Origins and implications
11. On the genesis and regulation of cellular heterogeneity in malignant tumors
12. Tumor heterogeneity: Biological implications and therapeutic consequences
13. Tumor heterogeneity
14. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor
15. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy
16. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
17. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
18. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
19. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
20. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
21. Cell selection from a murine tumour using the fluorescent probe Hoechst 33342
22. Reciprocal paracrine interactions between tumor cells and endothelial cells. The "angiogenesis progression" hypothesis
23. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors
24. Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours
25. The histological structure of some human lung cancers and the possible implications for radiotherapy
26. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status
27. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1-alpha
28. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression
29. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation
30. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases
31. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
32. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth
33. Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents
34. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression
35. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
36. Marked induction of the lAP family anti-apoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
37. Control of apoptosis during angiogenesis by survivin expression in endothelial cells